Ireland
--:--IST
Recruiting Not applicable

Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy in Hemiplegic Stroke

NCT07668349 · tracked via the Priya Life Science Turkey tracker
Sponsor
Nisa Kiliç Koçak
Phase
Not applicable
Started
2026-02-19
Last updated
2026-06-25

Condition(s) studied

Stroke,Hemiplegia

Investigational drug(s) / intervention(s)

Mirror TherapyModified Constraint-Induced Movement Therapy

Mirror Therapy: Mirror therapy protocols targeting upper extremity motor functions for 4 weeks.

Modified Constraint-Induced Movement Therapy: Modified constraint-induced movement therapy (modified CIMT) protocols targeting the affected upper extremity for 4 weeks.

Study summary

The purpose of this study is to investigate and compare the effects of Modified Constraint-Induced Movement Therapy (mCIMT) and Mirror Therapy (MT) on upper extremity motor functions, activity participation, and independence in daily living activities among hemiplegic stroke patients. Participants diagnosed with stroke will be randomly assigned to intervention groups. The study aims to determine which therapeutic modality provides a higher contribution to the functional recovery of the paretic upper limb and overall quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \* Diagnosis: Confirmed first ischemic or hemorrhagic stroke with clinical and neurological evaluation. * Time Since Stroke: 3 to 24 months post-stroke onset. * Hemiplegia: Significant motor deficit in the affected upper extremity. * Motor Function Level: Presence of mild to moderate motor impairment in the affected upper extremity (FMA-UE score appropriate for the application of modified CIMT and mirror therapy). * Cognitive Status: Adequate cognitive capacity to understand and follow the study protocols (Mini-Mental State Examination score of 20 or above). * Visual Perception: Adequate visual perception to perform mirror therapy. * Comorbidities: Absence of severe coexisting medical conditions that prevent participation (e.g., uncontrolled cardiovascular diseases, severe psychiatric disorders). * Prior Treatments: No prior intensive participation in the interventions investigated in this study (modified CIMT or mirror therapy). * Consent: Voluntary agreement to participate and signed informed consent form. Exclusion Criteria: * \* Uncontrolled diabetes or other metabolic disorders. * Progressive non-stroke neurological diseases (e.g., Parkinson's disease, multiple sclerosis). * Terminal illness or short life expectancy. * Severe cognitive impairment preventing comprehension or execution of the study protocols (e.g., advanced dementia). * Severe visual impairment that prevents mirror therapy application (e.g., uncorrected visual acuity loss, neglect). * Severe visuospatial perception disorders making it difficult to perceive or interpret the mirror image. * Absence or minimal level of active movement in the affected upper extremity (limiting the applicability of modified CIMT). * Significant motor deficit in the unaffected upper extremity. * Severe and uncontrolled spasticity in the upper extremity.

Primary outcome measure(s)

  • Fugl-Meyer Assessment-Upper Extremity (FMA-UE) — Baseline (pre-treatment) and 4 weeks (post-treatment)
    The FMA-UE is an index used to assess sensorimotor function in stroke patients. It evaluates reflex activity, volitional movement, and coordination of the upper extremity. The total score ranges from 0 to 66, with higher scores indicating better upper extremity motor function.
  • Stroke Rehabilitation Assessment of Movement (STREAM) — Baseline (pre-treatment) and 4 weeks (post-treatment)
    The STREAM is a clinical measure of motor functioning for stroke patients. It evaluates upper limb movements, lower limb movements, and basic mobility. The total score ranges from 0 to 30 for each subscale, with higher scores reflecting better motor performance and mobility.

Trial sites (1)

FacilityCityRegionStatus
Akay Special Education and Rehabilitation Center Kastamonu Merkez Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07668349 on ClinicalTrials.gov ↗ ← All trials in Turkey